Skip to main content
. 2011 Apr 15;25(7):1135–1146. doi: 10.1038/leu.2011.50

Figure 1.

Figure 1

GSI-I treatment induces apoptosis in pre-B-cell lines and primary patient blasts. (a) Precursor-B ALL cell viability for 697 cells was abolished after 18 h treatment with GSI-I (Z-LLNle-CHO), reduced by 80% after treatment with MG132 and unaffected by treatment with three other GSI compounds. (b) GSI-1 induces cell death in precursor-B ALL cell lines with different cytogenetic characteristics. Tanoue B cells were relatively resistant to GSI-I. (c) Overnight treatment of blast cells from children and young adult patients led to 50–99% loss in cell viability, compared with only 10% loss of viability for normal peripheral blood B cells. (d) GSI-I inhibits proteosome activity at levels comparable to MG132 and bortezomib. (e) Bortezomib-induced cell death in patient samples is comparably less than that induced by GSI-I, as demonstrated in (d).